2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation (ISHLT)

  • Nazzareno Galiè
  • , Marc Humbert
  • , Jean-Luc Vachiery
  • , Simon Gibbs
  • , Irene Lang
  • , Adam Torbicki
  • , Gérald Simonneau
  • , Andrew Peacock
  • , Anton Vonk Noordegraaf
  • , Maurice Beghetti
  • , Ardeschir Ghofrani
  • , Miguel Angel Gomez Sanchez
  • , Georg Hansmann
  • , Walter Klepetko
  • , Patrizio Lancellotti
  • , Marco Matucci
  • , Theresa McDonagh
  • , Luc A Pierard
  • , Pedro T Trindade
  • , Maurizio Zompatori
  • Marius Hoeper, Victor Aboyans, Antonio Vaz Carneiro, Stephan Achenbach, Stefan Agewall, Yannick Allanore, Riccardo Asteggiano, Luigi Paolo Badano, Joan Albert Barberà, Hélène Bouvaist, Héctor Bueno, Robert A Byrne, Scipione Carerj, Graça Castro, Çetin Erol, Volkmar Falk, Christian Funck-Brentano, Matthias Gorenflo, John Granton, Bernard Iung, David G Kiely, Paulus Kirchhof, Barbro Kjellstrom, Ulf Landmesser, John Lekakis, Christos Lionis, Gregory Y H Lip, Stylianos E Orfanos, Myung H Park, Massimo F Piepoli, Piotr Ponikowski, Marie-Pierre Revel, David Rigau, Stephan Rosenkranz, Heinz Völler, Jose Luis Zamorano

Research output: Contribution to journalArticlepeer-review

2734 Citations (Scopus)
Original languageEnglish
Pages (from-to)67-119
Number of pages58
JournalEuropean Heart Journal
Volume37
Issue number1
Early online date29 Aug 2015
DOIs
Publication statusPublished - 1 Jan 2016

Keywords

  • Guidelines
  • Pulmonary hypertension
  • Pulmonary arterial hypertension
  • Chronic thromboembolic pulmonary hypertension
  • Congenital heart disease
  • Connective tissue disease
  • Heart failure
  • Respiratory failure
  • Endothelin receptor antagonists
  • Phosphodiesterase type 5 inhibitors
  • Prostacyclin analogues
  • Lung disease
  • Left heart disease

Cite this